Payment overview · 2025
General Payments
$1,636.12
86 reported records · 17 companies
Healthcare provider profile · identity verified
Courtney James Freeman, APRN-BC
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · GREENSBORO, NC · NPI 1235778317
Verified facts
What the public records show
CMS Open Payments records show Courtney James Freeman, APRN-BC received $1,636.12 in general payments during 2025 across 86 reported records.
Janssen Biotech, Inc. accounted for 22.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 23 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Linzess.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Lumigan by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 24 records involving 23 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Xarelto by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 159 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $371.93 | 22.7% | 18 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $251.45 | 15.4% | 14 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $183.34 | 11.2% | 11 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $139.65 | 8.5% | 7 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $139.03 | 8.5% | 8 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $111.32 | 6.8% | 6 | 2025 |
| Madrigal Pharmaceuticals | Unresolved — no canonical attribution shown | $93.80 | 5.7% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $76.60 | 4.7% | 4 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $49.03 | 3.0% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $45.68 | 2.8% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $35.11 | 2.1% | 3 | 2025 |
| Tempus AI, Inc | Unresolved — no canonical attribution shown | $28.64 | 1.8% | 1 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $27.15 | 1.7% | 1 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $25.49 | 1.6% | 1 | 2025 |
| Ipsen Biopharmaceuticals, Inc | Unresolved — no canonical attribution shown | $23.13 | 1.4% | 1 | 2025 |
| Braintree Laboratories, Inc. | Unresolved — no canonical attribution shown | $20.40 | 1.2% | 1 | 2025 |
| Mallinckrodt Hospital Products Inc. | Unresolved — no canonical attribution shown | $14.37 | 0.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,636.12 | 86 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TREMFYA Normalized: tremfya |
Drug | Janssen Biotech, Inc. | $371.93 | 18 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $251.45 | 14 | 2025 |
Source payment records
|
|||||
| SIMPONI Normalized: simponi |
Biological | Janssen Biotech, Inc. | $218.28 | 11 | 2025 |
Source payment records
|
|||||
| SIMPONI ARIA Normalized: simponi aria |
Biological | Janssen Biotech, Inc. | $218.28 | 11 | 2025 |
Source payment records
|
|||||
| STELARA Normalized: stelara |
Biological | Janssen Biotech, Inc. | $218.28 | 11 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $139.65 | 7 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $139.03 | 8 | 2025 |
Source payment records
|
|||||
| REZDIFFRA Normalized: rezdiffra |
Drug | Madrigal Pharmaceuticals | $93.80 | 4 | 2025 |
Source payment records
|
|||||
| RINVOQ Normalized: rinvoq |
Biological | ABBVIE INC. | $91.91 | 5 | 2025 |
Source payment records
|
|||||
| SKYRIZI Normalized: skyrizi |
Biological | ABBVIE INC. | $91.91 | 5 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $91.43 | 6 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $91.43 | 6 | 2025 |
Source payment records
|
|||||
| VELSIPITY Normalized: velsipity |
Drug | PFIZER INC. | $76.60 | 4 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | GENZYME CORPORATION, Regeneron Healthcare Solutions, Inc. | $76.18 | 4 | 2025 |
Source payment records
|
|||||
| ENTYVIO Normalized: entyvio |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $75.25 | 4 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $45.68 | 2 | 2025 |
Source payment records
|
|||||
| EOHILIA Normalized: eohilia |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $36.07 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $35.11 | 3 | 2025 |
Source payment records
|
|||||
| XT CDX Normalized: xt cdx |
Device | Tempus AI, Inc | $28.64 | 1 | 2025 |
Source payment records
|
|||||
| IQIRVO Normalized: iqirvo |
Drug | Ipsen Biopharmaceuticals, Inc | $23.13 | 1 | 2025 |
Source payment records
|
|||||
| SUFLAVE Normalized: suflave |
Drug | Braintree Laboratories, Inc. | $20.40 | 1 | 2025 |
Source payment records
|
|||||
| SUTAB Normalized: sutab |
Drug | Braintree Laboratories, Inc. | $20.40 | 1 | 2025 |
Source payment records
|
|||||
| TERLIVAZ Normalized: terlivaz |
Drug | Mallinckrodt Hospital Products Inc. | $14.37 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 24 supporting records · 23 recipient NPIs · example record 1174259978 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
159 | 20 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 520 | 57 |
| Furosemide | Furosemide | 290 | 38 |
| Atorvastatin Calcium | Atorvastatin Calcium | 286 | 38 |
| Sertraline Hcl | Sertraline Hcl | 211 | 26 |
| Metoprolol Succinate | Metoprolol Succinate | 202 | 28 |
| Pantoprazole Sodium | Pantoprazole Sodium | 200 | 36 |
| Donepezil Hcl | Donepezil Hcl | 185 | 22 |
| Lisinopril | Lisinopril | 171 | 22 |
| Potassium Chloride | Potassium Chloride | 171 | 23 |
| Losartan Potassium | Losartan Potassium | 166 | 20 |
| Eliquis | Apixaban | 159 | 20 |
| Amlodipine Besylate | Amlodipine Besylate | 156 | 21 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 156 | 20 |
| Mirtazapine | Mirtazapine | 154 | 21 |
| Metoprolol Tartrate | Metoprolol Tartrate | 148 | 21 |
| Omeprazole | Omeprazole | 145 | 34 |
| Trazodone Hcl | Trazodone Hcl | 134 | 19 |
| Metformin Hcl | Metformin Hcl | 130 | 17 |
| Escitalopram Oxalate | Escitalopram Oxalate | 126 | 17 |
| Gabapentin | Gabapentin | 115 | 16 |
| Alendronate Sodium | Alendronate Sodium | 112 | 12 |
| Tramadol Hcl | Tramadol Hcl | 111 | 26 |
| Carvedilol | Carvedilol | 108 | 11 |
| Famotidine | Famotidine | 104 | 20 |
| Clopidogrel | Clopidogrel Bisulfate | 103 | 11 |
| Divalproex Sodium | Divalproex Sodium | 92 | 12 |
| Hydralazine Hcl | Hydralazine Hcl | 88 | 12 |
| Memantine Hcl | Memantine Hcl | 88 | 15 |
| Pravastatin Sodium | Pravastatin Sodium | 84 | 12 |
| Tamsulosin Hcl | Tamsulosin Hcl | 83 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 79 | 30 |
| Peg 3350-Electrolyte | Sodium Chloride/Nahco3/Kcl/Peg | 79 | 79 |
| Simvastatin | Simvastatin | 77 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 74 | 11 |
| Fluticasone Propionate | Fluticasone Propionate | 73 | 19 |
| Spironolactone | Spironolactone | 71 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 65 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 64 | 11 |
| Buspirone Hcl | Buspirone Hcl | 57 | 13 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 56 | suppressed |
| Latanoprost | Latanoprost | 53 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 50 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 45 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 44 | suppressed |
| Allopurinol | Allopurinol | 43 | suppressed |
| Januvia | Sitagliptin Phosphate | 41 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 40 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 40 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 39 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 39 | 14 |
| Xarelto | Rivaroxaban | 39 | suppressed |
| Ezetimibe | Ezetimibe | 36 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 36 | suppressed |
| Jardiance | Empagliflozin | 35 | suppressed |
| Lorazepam | Lorazepam | 35 | 13 |
| Midodrine Hcl | Midodrine Hcl | 35 | suppressed |
| Glipizide | Glipizide | 33 | suppressed |
| Lamotrigine | Lamotrigine | 33 | suppressed |
| Glimepiride | Glimepiride | 32 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 32 | suppressed |
| Nyamyc | Nystatin | 30 | 17 |
| Benztropine Mesylate | Benztropine Mesylate | 28 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 28 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 27 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 27 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 26 | suppressed |
| Irbesartan | Irbesartan | 26 | suppressed |
| Creon | Lipase/Protease/Amylase | 25 | suppressed |
| Myrbetriq | Mirabegron | 24 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 24 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 23 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 23 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 23 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 22 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 22 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 22 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 21 | suppressed |
| Gavilyte-G | Peg3350/Sod Sulf,bicarb,cl/Kcl | 21 | 21 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 21 | 19 |
| Valsartan | Valsartan | 21 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 20 | suppressed |
| Finasteride | Finasteride | 20 | suppressed |
| Leflunomide | Leflunomide | 20 | suppressed |
| Meloxicam | Meloxicam | 20 | suppressed |
| Celecoxib | Celecoxib | 19 | suppressed |
| Lidocaine | Lidocaine | 19 | suppressed |
| Prednisone | Prednisone | 19 | suppressed |
| Anastrozole | Anastrozole | 18 | suppressed |
| Atenolol | Atenolol | 18 | suppressed |
| Timolol Maleate | Timolol Maleate | 18 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 17 | suppressed |
| Entresto | Sacubitril/Valsartan | 17 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 17 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 17 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 17 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 17 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 16 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 16 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 16 | suppressed |
| Linzess | Linaclotide | 16 | suppressed |
| Nystop | Nystatin | 16 | suppressed |
| Alprazolam | Alprazolam | 15 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 15 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 15 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 15 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 14 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 14 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 14 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 14 | suppressed |
| Gemtesa | Vibegron | 13 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 13 | suppressed |
| Loperamide | Loperamide Hcl | 13 | 11 |
| Methenamine Hippurate | Methenamine Hippurate | 13 | suppressed |
| Nystatin | Nystatin | 13 | 12 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 13 | suppressed |
| Rhopressa | Netarsudil Mesylate | 13 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 13 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 13 | suppressed |
| Topiramate | Topiramate | 13 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 13 | suppressed |
| Aripiprazole | Aripiprazole | 12 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 12 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 12 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 12 | 12 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 12 | suppressed |
| Lumigan | Bimatoprost | 12 | suppressed |
| Ramipril | Ramipril | 12 | suppressed |
| Restasis | Cyclosporine | 12 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 12 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 11 | suppressed |
| Fluconazole | Fluconazole | 11 | suppressed |
| Galantamine Er | Galantamine Hbr | 11 | suppressed |
| Neupro | Rotigotine | 11 | suppressed |
| Pregabalin | Pregabalin | 11 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 11 | suppressed |
| Sulindac | Sulindac | 11 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,636.12 · 86 records | Janssen Biotech, Inc. | CREON, DUPIXENT, ENTYVIO, EOHILIA, IBSRELA, IQIRVO, LINZESS, REZDIFFRA, RINVOQ, SIMPONI, SIMPONI ARIA, SKYRIZI, STELARA, SUFLAVE, SUTAB, TERLIVAZ, TREMFYA, VELSIPITY, VOQUEZNA, Wegovy, XIFAXAN, XT CDX, ZENPEP | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error